Company ProfilePremium

ATS Corporation

Company Profile Analysis

Ticker: ATS.TO

ESOMAR 23 Corporate BadgeISO Certifications Badge
ATS Corporation - Company showcase

Year Founded & Workforce

1978

7,000 Employees

ATS Corporation logo

ATS Corporation Employee Contacts

57 verified contactsNames, job titles, seniority and locations

View Employee Contacts

ATS Corporation Overview

ATS Corporation is one of the world's largest independent automation solutions providers. It designs, builds, commissions and services custom and repeatable automated manufacturing, assembly, test, processing and packaging systems for multinational customers in regulated, high-reliability markets. Life sciences is its largest vertical, accounting for 51% of FY2026 adjusted revenue. It is followed by consumer products and warehouse packaging, food and beverage (including global tomato-processing leadership through CFT), energy (notably CANDU nuclear refurbishment and small-modular-reactor programs) and a shrinking, now-repositioned transportation/EV business. FY2026 adjusted revenue was C$2.97 billion. Roughly one-third of revenue is reoccurring aftermarket, spares and repeat product revenue, which partly cushions the project cycle. ATS combines a decentralized, acquisition-built portfolio with a lean operating system, the ATS Business Model (ABM). Under a new CEO, it is resetting its cost base through an 18-month Fixed Cost Transformation Program aimed at a 15% adjusted operating margin.


Company's own description (FY2026 / Q1 FY2027 disclosure)

ATS describes itself as an industry-leading automation solutions provider to many of the world's most successful companies. It says it applies its knowledge base and global capabilities across custom automation, repeat automation, automation products, and value-added solutions including pre-automation and after-sales services. These capabilities address the manufacturing automation and service needs of multinational customers. In the Q1 FY2027 boilerplate the end-markets are listed as life sciences, food and beverage, industrial and consumer, and energy. Transportation was folded into "industrial & consumer" from Q1 FY2027.

What ATS actually does — independent characterization

ATS is best understood as a portfolio of engineered-equipment and systems-integration businesses run under a common operating system and capital-allocation framework. It operates at four layers of the industrial value chain:

  1. Pre-automation and engineering. Concept design, simulation, process development, digital and MES integration (Process Automation Solutions, IPCOS, IT.ACA) and front-end engineering for nuclear and SMR programs.

  2. Custom integration and automation systems. Turnkey, one-off or low-volume production lines. Examples include auto-injector and wearable-device assembly for pharma (GLP-1 programs), contact-lens lines, pre-filled syringe lines, EV battery-module assembly historically, and nuclear fuel-handling and refurbishment tooling.

  3. Products and equipment. Standardized or modular machines and platforms, sold repeatedly. Examples are SuperTrak linear-motor conveyance, freeze-dryers and laboratory equipment (SP Industries), radiopharmaceutical isolators and hot cells (Comecer), tube fillers and cartoners (IWK), packaging machinery (Paxiom, NCC), tomato and fruit processing lines (CFT), optical sorters (Raytec Vision), and laboratory-animal water systems (Avidity Science).

  4. Services including spare parts. Aftermarket parts, retrofits, upgrades, field service, digital and consulting services across a large installed base. Management is embedding services directly into operating units to capture lifecycle revenue.

Revenue model mix

Revenue type (FY2026)CAD Mn% of total
Revenues from construction contracts (percentage-of-completion project revenue)1,599.253.8
Services rendered723.924.4
Sale of goods647.021.8
Total2,970.1100.0
Offering (FY2026)CAD Mn% of total
Custom integration and automation systems1,033.734.8
Products and equipment927.131.2
Services including spare parts1,009.334.0
Total2,970.1100.0

ATS discloses revenue on three overlapping bases.

By contract type (FY2026, adjusted revenue C$2,970.1M, source: Q4 FY2026 release)

By offering (FY2026)

The mix has shifted meaningfully toward products and services. Custom integration was 46.9% of revenue in FY2024 (C$1,422.3M of C$3,032.9M) and is 34.8% in FY2026, while services including spares rose from 27.3% to 34.0%. Management guides that "reoccurring revenues" will be 25%–35% of trailing-twelve-month revenue. On the Q4 FY2026 call, management said reoccurring revenue was about one-third of FY2026 revenue. ATS has no meaningful subscription or licensing revenue line. Software revenue (MES, Illuminate-type data platforms, PA digital services) is embedded in services and custom integration. In Q1 FY2027 ATS took a C$7.1M impairment on deferred development assets in its "smaller software-focused businesses."

Customer types and end-markets

Customers are predominantly large multinationals: global pharmaceutical and medical-device companies, consumer-goods and e-commerce/warehouse operators, food and beverage processors, nuclear utilities and fuel fabricators, and automotive/EV OEMs and tier-1s, although this last group is being de-emphasized. The Q4 FY2026 release highlighted several large enterprise life-sciences programs with long performance periods. ATS flags customer-concentration risk in its AIF, and the FY2025 C$171.1M settlement with a single EV customer shows how a single program can swing results.

FY2026 adjusted revenue by market: life sciences 51.2%, consumer products 18.6%, food and beverage 16.8%, energy 7.6%, transportation 5.7%. Entering FY2027, about 80% of backlog is in regulated markets (life sciences, energy, food and beverage), per the Q4 FY2026 call.

Value-chain position and economics

ATS sits between component and robot suppliers (servo, PLC, vision, robotics vendors) and end manufacturers. Its value-add is application engineering, integration risk-taking and validated-process know-how, especially for regulated GMP and nuclear environments.

The economics are structurally mid-margin:

  • FY2026 gross margin was 28.6% (calculated from IFRS revenue less cost of revenues).

  • The adjusted operating margin (adjusted earnings from operations, "AEO") was 10.6%.

  • The adjusted EBITDA margin was 13.9%.

These margins sit below proprietary-product automation peers but above pure integrators. Working-capital intensity is significant because contract assets and milestone billing create cash-flow volatility. Non-cash working capital was 22.4% of revenue at FY2025 and 12.1% at FY2026.

Strategy

Stated strategy (FY2026 annual report / MD&A and Q1 FY2027)

ATS's value-creation strategy has three pillars:

  • Organic growth, outgrowing its chosen end markets through global scale, technology differentiation and the ABM.

Disciplined acquisitions: that give access to attractive end markets, products and technologies at hurdle-rate returns.

Margin expansion: through the ABM, commercial discipline, aftermarket mix and cost actions.

It is underpinned by the ATS Business Model (ABM), a lean, Danaher-style operating system covering strategy deployment, kaizen, standard work and talent.

Under Doug Wright, the framing has shifted toward a "Growth Algorithm" focused on per-share cash generation. It combines organic growth, disciplined M&A, margin expansion and better working-capital efficiency, supported by a cash return on investment (CROI) and ROIC capital-allocation framework (Q1 FY2027 release). Management has said the program "is not intended to alter" the strategic focus on services or the end markets served.

Strategic initiatives — last 24 months

InitiativeAnnouncedScopeTargets / status
Fixed Cost Transformation Program6 August 2026Multi-phase, about 18-month program to simplify the operating structure, optimize the global footprint and cut facility overhead, indirect costs and SG&AExpected to deliver about half of the margin expansion needed to reach the 15% adjusted EFO target. Phase 1 (European Footprint Consolidation): about C$20M annual savings, about 30% of the total opportunity. Implied total program savings about C$65–70M a year (calculated from the 30% figure). Program costs not yet disclosed.
Transportation reorganization and repositioningQ4 FY2026 (May 2026)Consolidate transportation-focused divisions; sell surplus facilities; redeploy laser welding, vision and precision test capabilities to data-center, warehouse and industrial usesC$28.3M charge in Q4 FY2026 and C$9.2M in Q1 FY2027. About C$50M of dilutive revenue exits in FY2027. Transportation no longer reported separately from Q1 FY2027.
Services reorganizationFY2026Embed services in operating units for installed-base accountability and lifecycle captureC$9.8M (Q4 FY2026) and C$4.7M (Q1 FY2027) of redundant-asset costs. Aims to lift reoccurring revenue above the 25–35% range over time.
Lab-equipment go-to-market reorganizationFY2026Coordinated commercial approach across SP Industries, Avidity and other lab businessesEarly pipeline building (FY2026 and Q1 FY2027 MD&A).
Software-business portfolio reviewQ1 FY2027Reassessment of deferred development assets in smaller software-focused businessesC$7.1M impairment.
Nuclear and SMR investmentOngoingReinvest part of the reorganization savings in nuclear; FEED, prototype and fuel-fabrication automationEnergy backlog up 40% year over year at FY2026.
RadiopharmaceuticalsOngoingComecer containment plus ATS integration and lifecycle support across the radiopharma value chainRepeat bookings in Q4 FY2026 and Q1 FY2027.
ERP upgrade and ICFR remediationFY2026–FY2027Upgrade ERP in one international division to fix a material weaknessImplementation planned within FY2027.
Capital return: NCIBDecember 2025Repurchase up to 8,225,621 shares (as announced)1,119,413 shares bought through August 2026 at an average of C$27.97. Management expects to stay active.
Restructuring program, FY2025–FY2026FY2025 / Q3 FY2026Cost-structure actionsAbout C$20M expected in Q3–Q4 FY2026; C$23.1M recorded in FY2026.

Sustainability commitments

ATS frames part of its funnel around customer decarbonization: nuclear, grid storage and sustainable packaging. Specific corporate emissions targets were not found in the documents reviewed.

Management guidance and medium-term targets

ItemGuidance / targetSource
Q2 FY2027 revenueC$660M–C$700MQ1 FY2027 release
FY2027 revenue"Modest" organic growth, now contingent on stronger bookings and execution in H2 FY2027; includes about C$50M transportation exitQ4 FY2026 and Q1 FY2027 releases
FY2027 adjusted EFO margin+50 to +75 bps year over year, not linear by quarterQ4 FY2026 release
Long-term adjusted EFO margin15% (unchanged; may be updated as progress is made)Q4 FY2026 and Q1 FY2027
Leverage2.0x–3.0x net debt / pro forma adjusted EBITDA throughout FY2027Q1 FY2027
Non-cash working capitalBelow 15% of annualized revenue (long-term)Q4 FY2026
Reoccurring revenue25%–35% of trailing-twelve-month revenueQ1 FY2027
FY2027 capex plus intangiblesC$70M–C$90MQ1 FY2027 call
Q1 FY2027 restructuringC$10M–C$15M expected; C$5.7M recorded, with the remainder shifting to Q2–Q3Q1 FY2027
Long-term growthGrow revenue faster than chosen end marketsQ4 FY2026

The Q4 FY2026 release also refers to a "multi-year free cash flow target" in forward-looking statements. The numeric target was not found in the excerpts reviewed.

Products & Services

Note: ATS does not publish a consolidated product catalog with pricing. Pricing is project-quoted. Unit prices are not publicly disclosed for any line. Brand lists below are drawn from ATS releases (including the May 2024 Paxiom announcement, which named CFT, Raytec Vision, Marco, IWK and NCC as packaging and food businesses) and acquisition disclosures. Launch and latest-version years are given only where known.

Life Sciences

Offering / brandDescription & capabilitiesTarget customerNotes
ATS Life Sciences custom automationTurnkey automated assembly and test lines for auto-injectors, pen injectors, wearable drug-delivery devices, contact lenses, pre-filled syringes, diagnostics, inhalers and catheters. GMP-validated.Global pharma, biotech and medtech (including GLP-1 drug-delivery producers)Flagship of the large enterprise programs. Management expected GLP-1-related revenue to move toward a high-single-digit % of total revenue (FY2024 outlook). Activity normalized in FY2027.
SortimatMedical-device and pharmaceutical assembly automation (Germany)Medtech and pharma OEMsAcquired 2011 (about $62M).
IWK VerpackungstechnikTube-filling machines, cartoners and secondary packaging for pharma and cosmeticsPharma and consumer healthAcquired about 2014. Also serves consumer markets.
ComecerRadiopharmaceutical containment: isolators, hot cells, dispensing and synthesis containment, aseptic processingRadiopharma producers, nuclear medicine, isotope producers, hospitalsCore of the radiopharmaceutical strategy. Q4 FY2026 and Q1 FY2027 bookings included radiopharma orders.
SP Industries (SP Scientific and related brands)Freeze-dryers (lyophilization), laboratory evaporators, temperature-controlled equipment and lab suppliesPharma R&D, CDMOs, academic and government labsExposed to constrained U.S. lab funding; a coordinated lab-equipment go-to-market reorganization is under way (FY2026 MD&A).
Avidity ScienceWater purification and related systems for life-science research facilitiesResearch institutions, pharma vivariumsAcquired FY2024.
Automated pharmacy solutionsAutomation for pharmacy dispensing and fulfillmentPharmacies, health systemsNamed in the FY2026 outlook funnel.

Industrial & Consumer (formerly Consumer Products and Transportation)

Offering / brandDescription & capabilitiesTarget customerNotes
SuperTrak CONVEYANCE (including SuperTrak GEN3)Intelligent linear-motor conveyance platform with independently controlled movers for high-speed flexible assembly; used inside ATS systems and sold to third-party OEMs and integratorsConsumer goods, medtech, battery and electronics manufacturers; OEM machine buildersATS's best-known proprietary product platform.
Warehouse packaging automationAutomated packaging and end-of-line systems for e-commerce and fulfilmentE-commerce, retail and consumer logisticsDriver of the 80.6% Q4 FY2026 consumer-products revenue increase.
Paxiom Group (including product lines such as weigh-filling, bagging, wrapping, labeling, conveyors, case forming, robotic case packing and palletizing)Primary, secondary and end-of-line packaging machinesFood and beverage, cannabis, pharmaAcquired FY2025; complements CFT, Raytec, Marco, IWK and NCC.
NCC Automated SystemsPackaging automation equipmentConsumer and pharma packagingNamed in the Paxiom release as an ATS packaging business.
Repositioned transportation capabilitiesLaser welding, machine vision, high-precision test, battery module and pack assembly, e-drive and powertrain testAutomotive/EV OEMs and tier-1s; being redeployed toward data-center infrastructure and other mission-critical industrial productionThree smaller U.S. facilities closing. Two U.S. facilities and one German facility held for sale. About C$50M of dilutive revenue to be exited in FY2027.
High-speed assembly for consumer goodsCustom lines for personal care, household products, electronics and appliancesConsumer-goods multinationalsHistoric core competence.

Food & Beverage

Offering / brandDescription & capabilitiesTarget customerNotes
CFT S.p.A. (including the Rossi & Catelli heritage brand)Complete tomato-processing and soft-fruit/vegetable processing lines (extraction, concentration, aseptic processing), beverage filling and packagingTomato processors, fruit and vegetable processors, beverage bottlersATS cites strong global brand recognition in tomato processing. Expanding into fresh fruit, secondary processing and packaging.
Raytec VisionOptical inspection and sorting systems for foodFood processorsItalian; part of the food platform.
Marco LimitedFood and packaging-line equipment (UK)Food producersNamed in the May 2024 release as part of the packaging portfolio.
Paxiom (food lines)See 5.2Food producersCross-vertical.

Energy

OfferingDescription & capabilitiesTarget customerNotes
Nuclear refurbishment and life-extensionSpecialized tooling and automation for CANDU reactor refurbishment, including fuel-handling, inspection and specialized test systems for high-risk environmentsCanadian nuclear utilities and international CANDU operatorsLong track record. Q4 FY2026 energy revenue up 101.5%.
SMR and new-build engineeringFront-end engineering, design and prototype equipment for small modular reactors and conventional new builds; automation for modular fabrication and assemblyReactor vendors, utilitiesManagement estimates ATS's addressable share at a low-single-digit % of total reactor-program capex, depending on application (Q1 FY2027 release).
Nuclear fuel fabrication automationAutomation for fuel fabrication facilities ahead of reactor deploymentFuel fabricatorsCalled out in Q1 FY2027 as a complementary opportunity.
Grid battery storageAssembly automation for stationary storageEnergy-storage manufacturersNamed in the FY2026 outlook.

Cross-portfolio digital, process automation and services

OfferingDescriptionNotes
Process Automation Solutions (PA)Industrial automation, MES/MOM, process control, digitalization and OT/IT integration across pharma, food and chemicalsPlatform augmented by IPCOS (Belgium), IT.ACA (Italy), Zi-Argus (Australia/Thailand) and Triad Unlimited.
Illuminate manufacturing intelligence (ATS software)Data-collection and production-analytics software for ATS-built and third-party linesPart of the "data-enabled automation" strategy. The Q1 FY2027 software-asset impairment signals re-scoping of smaller software units.
Lifecycle servicesSpares, retrofits, upgrades, relocation, field service and performance improvementServices incl. spares revenue C$1,009.3M in FY2026; now embedded in operating units (services reorganization).

Financial Narrative

Sources: FY2022 release (May 2022); FY2023 release (18 May 2023); FY2024 release (16 May 2024); FY2026 release (28 May 2026, with FY2025 comparatives). FY2022 detail beyond revenue, net income and EPS was not available in the documents reviewed.

Income statement

FY2022 basic EPS is from roic.ai and is consistent with net income of C$121.4M on about 92M shares. FY2022 revenue of C$2,182.7M is the comparative shown in ATS's FY2023 filings.

Margins (%)

Revenue CAGR: FY2022–FY2026 is 8.0% a year (calculated, IFRS). FY2023–FY2026 is 4.9% a year. Organic growth was 10.7% in FY2024, 6.0% in FY2026 and -6.4% in Q1 FY2027.

Quarterly run-rate

Q2 and Q3 FY2026 revenue and Q2 net income are calculated from disclosed half-year and full-year totals. Q3 net income of C$29.94M is per the RTTNews report of the 4 February 2026 release.

Balance sheet

FY2022 cash is the FY2023 opening balance. At Q1 FY2027 (28 June 2026): cash C$198.9M, long-term debt C$1,234.5M, net debt C$1,192.0M, equity C$1,802.8M, non-cash working capital 14.3%, and assets held for sale C$61.4M.

Cash flow

Q1 FY2027 operating cash flow was -C$10.3M and free cash flow -C$25.9M, against C$155.8M and C$139.5M in Q1 FY2026. Management's FY2027 capex plus intangibles guidance is C$70M–C$90M.

Key ratios

How these were calculated:

  • ROIC = adjusted EFO × (1 − about 24% adjusted tax rate) ÷ (year-end equity + net debt).

  • FY2025 net debt/EBITDA is pro forma for acquisitions, per the company.

  • The cash conversion cycle excludes contract assets and contract liabilities, which are material for a percentage-of-completion business. The company's own non-cash-working-capital ratio is the better liquidity indicator.

Commentary on trends, inflections and drivers

Revenue. ATS crossed C$3B in FY2024 on transportation/EV programs and acquisitions (Avidity, IT.ACA). FY2025 IFRS revenue fell 16.5% to C$2,533M. Of that decline, C$146.9M reflects the one-time EV settlement. Adjusted revenue fell 11.6% to C$2,680M as EV collapsed, partly offset by GLP-1 life-sciences programs and the Paxiom acquisition.

FY2026 recovered to C$2,973M (+10.8% adjusted; 6.0% organic, 2.9% FX, 1.6% acquisitions). That recovery was driven by life sciences backlog conversion, consumer/warehouse packaging, food and beverage, and nuclear. FY2027 has started with an organic decline: Q1 was -6.4%, and Q2 is guided to C$660M–C$700M, down about 7% year over year at the midpoint.

Margins. The adjusted EFO margin compressed from 13.3% in FY2023 to about 10.5% in FY2025–FY2026. The adjusted EBITDA margin moved from about 15.5% to about 13.9%. The causes were:

  • loss of high-absorption EV volume against a fixed footprint built for a C$3B+ EV-inclusive business;

  • SG&A inflation, from C$445M (17.3% of revenue) in FY2023 to C$620M (20.9%) in FY2026, reflecting acquisitions, ERP/controls remediation and public-company costs;

  • mix effects as products and services grew.

Gross margin on adjusted revenue excluding adjustment items improved sequentially and year over year in Q1 FY2027, management says. However, operating deleverage pushed the Q1 FY2027 adjusted EFO margin down to 9.8%. The stated FY2027 goal is a 50–75 basis-point improvement in adjusted EFO margin, which looks challenging given Q1. The 15% long-term target implies roughly 450 basis points of expansion, half of which the new Fixed Cost Transformation Program is meant to deliver.

Earnings quality. The gap between IFRS and adjusted earnings is large and persistent. Adjusted net income was C$165.5M in FY2026 against IFRS net income of C$71.7M. The recurring adjustments are acquisition amortization (C$58.1M), restructuring (C$23.1M), and transportation and services reorganization (C$38.1M). Investors should treat restructuring as quasi-recurring: it has been C$22.8M–C$27.5M a year for four consecutive years, and Q1 FY2027 added another C$22.2M of reorganization-type items.

Cash flow and working capital. This is the most important inflection. FY2024 and FY2025 free cash flow was negative (-C$67.6M and -C$52.3M) as EV milestone billing lagged and contract assets swelled to C$704.7M at FY2024. In FY2026, working capital released C$246.6M, the non-cash working capital ratio fell from 22.4% to 12.1%, and free cash flow reached a record C$371.7M (125% of adjusted net income after excluding the release).

Q1 FY2027 reversed part of this. Operating cash flow was -C$10.3M and the working-capital ratio rose to 14.3%. That is still within the long-term goal of below 15%.

Leverage. Net debt peaked at C$1,474.5M (3.9x pro forma adjusted EBITDA) at FY2025 after the Paxiom acquisition and EV working-capital build. FY2026 debt repayment (C$331M) brought it to 2.8x. The ratio is now drifting up again (2.9x at Q1 FY2027) as trailing EBITDA declines. Management targets 2.0–3.0x throughout FY2027. Interest burden is material: net finance costs of C$99.6M consumed 32% of adjusted EFO in FY2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Markets

MarketFY2023FY2024FY2025FY2026

Life Sciences revenue (CAD Mn)

1,209.91,268.61,471.81,522.0

Transportation revenue (CAD Mn)

578.2933.3331.8169.7

Food & Beverage revenue (CAD Mn)

371.3435.0416.9498.8

Consumer Products revenue (CAD Mn)

305.1287.2335.7553.0

Energy revenue (CAD Mn)

112.9108.8124.0226.6

Total revenue (CAD Mn)

2,577.43,032.92,680.22,970.1

Markets (FY2024–FY2026)

MarketFY2024FY2025FY2026

Life Sciences YoY growth (%)

4.916.03.4

Transportation YoY growth (%)

61.4-64.4-48.9

Food & Beverage YoY growth (%)

17.2-4.219.6

Consumer Products YoY growth (%)

-5.916.964.7

Energy YoY growth (%)

-3.614.082.7

Total YoY growth (%)

17.7-11.610.8

Markets — Life Sciences share

MarketFY2023FY2024FY2025FY2026

Life Sciences share (%)

46.941.854.951.2

Transportation share (%)

22.430.812.45.7

Food & Beverage share (%)

14.414.315.616.8

Consumer Products share (%)

11.89.512.518.6

Energy share (%)

4.43.64.67.6

Markets (Quarterly)

Market (new basis)Q1 FY2026Q1 FY2027YoY %

Life Sciences

378.8345.9-8.7

Industrial & Consumer

184.0175.6-4.6

Food & Beverage

138.5117.0-15.5

Energy

35.459.868.9

Total adjusted revenue

736.7698.3-5.2

Markets — Life Sciences backlog

MarketFY2023FY2024FY2025FY2026

Life Sciences backlog (CAD Mn)

7618711,1991,077

Transportation backlog (CAD Mn)

939425214129

Food & Beverage backlog (CAD Mn)

215230258214

Consumer Products backlog (CAD Mn)

156156282278

Energy backlog (CAD Mn)

82111186260

Total backlog (CAD Mn)

2,1531,7932,1391,958

Revenue by Segment and Revenue by Segment (x)

MetricFY2023FY2024FY2025FY2026

Order Bookings (CAD Mn)

3,2562,8913,3052,952

Book-to-bill (x, calculated)

1.260.951.230.99

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue IFRS (CAD Mn)

2,182.72,577.43,032.92,533.32,972.9

Adjusted revenue (CAD Mn)

2,182.72,577.43,032.92,680.22,970.1

Cost of revenues (CAD Mn)

—1,851.62,177.41,886.62,122.1

Gross profit (CAD Mn, calculated)

—725.8855.5646.7850.9

SG&A (CAD Mn)

—445.2503.5604.2620.3

Restructuring costs (CAD Mn)

—27.522.824.023.1

Earnings from operations (CAD Mn)

—222.5315.49.3198.8

Adjusted earnings from operations (CAD Mn)

—343.4397.5282.6314.4

Depreciation & amortization (CAD Mn)

—125.5141.2152.7163.9

EBITDA (CAD Mn)

—348.0456.6162.0362.7

Adjusted EBITDA (CAD Mn)

—401.2470.6368.9413.0

Net finance costs (CAD Mn)

—62.768.792.299.6

Pre-tax income (CAD Mn)

—159.8246.7-82.999.2

Income tax expense (CAD Mn)

—32.152.5-55.027.5

Net income (CAD Mn)

121.4127.7194.2-28.071.7

Basic EPS (CAD)

1.321.391.98-0.290.73

Diluted EPS (CAD)

—1.381.97-0.290.73

Adjusted basic EPS (CAD)

—2.372.611.471.69

Dividends per share (CAD)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin IFRS (%)

—28.228.225.528.6

Operating margin EFO/revenue (%)

—8.610.40.46.7

Adjusted EFO margin (%)

—13.313.110.510.6

EBITDA margin (%)

—13.515.16.412.2

Adjusted EBITDA margin (%)

—15.615.513.813.9

Net margin (%)

5.65.06.4-1.12.4

Income Statement and Per-Share Data (Quarterly)

MetricQ1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027

Revenue IFRS (CAD Mn)

736.7728.5760.6747.1693.7

Net income (CAD Mn)

24.333.729.9-16.2-0.3

Adjusted EBITDA (CAD Mn)

101.5——102.592.9

Adjusted basic EPS (CAD)

0.41——0.360.35

Order Bookings (CAD Mn)

693734821704656

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (CAD Mn)

—3,543.84,088.84,621.94,340.0

Cash & equivalents (CAD Mn)

135.3159.9170.2225.9285.0

Bank indebtedness (CAD Mn)

—5.84.127.36.7

Short-term debt incl. current leases (CAD Mn)

—24.127.832.935.4

Long-term debt (CAD Mn)

—1,155.71,171.81,543.51,274.6

Long-term lease liabilities (CAD Mn)

—73.383.896.7119.5

Total debt incl. leases (CAD Mn, calculated)

—1,258.91,287.51,700.41,436.2

Net debt (CAD Mn)

—1,099.01,117.31,474.51,151.2

Total equity (CAD Mn)

—1,130.61,683.91,709.41,779.5

Goodwill (CAD Mn)

—1,118.31,228.61,394.61,399.3

Intangible assets (CAD Mn)

—593.2679.5758.5704.2

Working capital: current assets less current liabilities (CAD Mn, calculated)

—408.4724.5779.9668.2

Non-cash working capital (CAD Mn)

—278.5586.1614.2365.1

Non-cash working capital % of revenue

—10.119.022.412.1

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (CAD Mn)

—127.820.825.8448.4

Capex PP&E (CAD Mn)

—56.158.834.033.6

Intangible asset additions (CAD Mn)

—24.229.644.143.1

Free cash flow (CAD Mn)

—47.5-67.6-52.3371.7

Business acquisitions net of cash (CAD Mn)

—51.7276.5179.40

Dividends paid (CAD Mn)

00000

Share repurchases (CAD Mn)

—21.10.045.010.0

Shares acquired for RSU trust (CAD Mn)

—12.423.814.79.6

Net equity issued, U.S. IPO (CAD Mn)

—0362.100

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE on average equity (%)

—13.8-1.74.1

ROA on average assets (%)

—5.1-0.61.6

ROIC, adjusted after-tax (%)

11.710.86.78.3

Current ratio (x)

1.391.701.691.64

Debt-to-equity, company definition (x)

1.180.791.100.89

Net debt / adjusted EBITDA (x)

2.72.43.92.8

Interest coverage EFO / net finance (x)

3.54.60.12.0

Interest coverage adj. EFO / net finance (x)

5.55.83.13.2

Asset turnover (x)

—0.790.580.66

DSO, receivables only (days)

56.656.7103.764.3

DIO (days)

50.649.661.950.8

DPO, payables and accruals (days)

127.7101.3128.7107.1

Cash conversion cycle (days)

-20.55.036.98.0

Revenue by Region

RegionFY2023FY2024FY2025FY2026

North America revenue (CAD Mn)

1,525.51,766.51,432.01,558.6

Europe revenue (CAD Mn)

811.7990.1938.61,020.5

Asia/Other revenue (CAD Mn)

240.2276.3309.6391.0

Total revenue (CAD Mn)

2,577.43,032.92,680.22,970.1

Region Margins & Growth (%)

RegionFY2024FY2025FY2026

North America YoY growth (%)

15.8-18.98.8

Europe YoY growth (%)

22.0-5.28.7

Asia/Other YoY growth (%)

15.012.126.3

Revenue by Region (%)

RegionFY2023FY2024FY2025FY2026

North America share (%)

59.258.253.452.5

Europe share (%)

31.532.635.034.4

Asia/Other share (%)

9.39.111.613.2

Valuation Snapshot

MetricValueSource / note

NYSE price, early October 2026

About US$17.7–18.3 (52-week low US$17.72 on 7 October 2026)

MarketBeat

TSX price, 2 September 2026

C$26.29

Stockwatch

TSX 52-week high

C$49.48

WealthAwesome (mid-2026)

NYSE 52-week high

About US$35.82

AInvest (August 2026)

1-year performance

About -45% to -50% (TSX, calculated from the 52-week high and early-October level). Fintel reported -28.1% as of 21 August 2026.

Approximate

Key event moves

-11.5% intraday on 28 May 2026 (Q4 FY2026); -26.55% on 6 August 2026 (Q1 FY2027)

Stock Track; Levi & Korsinsky notice

Beta

1.18

MarketBeat

Valuation Multiples

MultipleATSBasis

Market cap (CAD Mn)

about 2,395

Calculated

Enterprise value (CAD Mn)

about 3,587

Market cap plus net debt (including leases)

P/E (IFRS, TTM)

about 51x

TTM basic EPS C$0.48 (MarketBeat shows 52.4x)

P/E (adjusted, TTM)

about 15x

TTM adjusted EPS C$1.63

EV / adjusted EBITDA (TTM)

about 8.9x

TTM pro forma adjusted EBITDA C$404.3M

EV / sales (TTM)

about 1.2x

TTM adjusted revenue about C$2,932M

P/B

about 1.3x

Book value per share about C$18.4

FCF yield (FY2026 FCF)

about 15%

C$371.7M / market cap; flattered by working-capital release

Capital Markets

ItemDetail

Coverage

About 17 analysts (Simply Wall St); 6–7 active in recent months

Rating mix (MarketBeat, October 2026)

3 Buy, 2 Hold, 2 Sell; consensus "Hold"

Rating mix (TipRanks, 3-month)

4 Buy, 2 Hold; "Moderate Buy"

Recent target actions

RBC C$50 → C$41 (10 August 2026); Stifel C$52 → C$44, Buy (7 August 2026); TD Securities Buy → Hold (10 August 2026); Scotiabank C$48 → C$51, Sector Outperform (28 April 2026, before the decline)

Consensus target

Sources conflict. MarketBeat shows US$42.50 (likely stale, pre-August). TipRanks NYSE shows US$32.95 (about 23% upside from US$26.88 when published).

Consensus EPS

MarketBeat: about US$1.12 for the current fiscal year (basis unclear)

Moody's / S&P / Fitch ratings

ATS has historically carried sub-investment-grade (high-yield) corporate ratings; current ratings and outlooks should be confirmed with the agencies.

Long-term debt (Q1 FY2027)

C$1,234.5M, plus C$155.3M of lease liabilities

Composition

Senior unsecured notes plus a senior secured revolving credit facility.

FY2026 debt activity

C$331.4M repaid; C$85.0M drawn

Q1 FY2027 debt activity

C$50.1M repaid

Cash interest paid

C$97.5M (FY2026)

Maturity profile

Not publicly disclosed in the documents reviewed (see the 40-F liquidity note). Current portion of long-term debt is only C$0.2M, so there is no near-term maturity wall within 12 months.

Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Dividends per share (CAD)

00000

Share repurchases (CAD Mn)

—21.10.045.010.0

Analyst Conclusions

Management guidance (as of 6 August 2026)

  • Q2 FY2027 revenue of C$660M–C$700M, about 7% lower year over year at the midpoint.

  • FY2027 "modest" organic growth, now explicitly dependent on stronger H2 bookings and faster execution. This is net of about C$50M of exited transportation revenue.

  • FY2027 adjusted EFO margin up 50–75 basis points (from 10.6%). Q1 delivered 9.8%, so H2 must improve materially.

  • Leverage of 2.0–3.0x throughout FY2027; capex plus intangibles of C$70M–C$90M.

  • Fixed Cost Transformation Program over about 18 months: Phase 1 about C$20M a year in Europe, about 30% of the total opportunity. Further phases and program costs to be disclosed.

  • Long-term 15% adjusted EFO margin target unchanged.

Consensus growth expectations

Directionally, the sell-side cut targets by 15–20% after Q1 FY2027 (RBC, Stifel) and moved toward Hold. MarketBeat's aggregated forecast implies current-year EPS of about US$1.12. The Q2 guidance midpoint of about C$680M sits below the roughly US$510M (about C$700M) consensus that preceded it.

Bull case

  1. Cost-out plus normalizing revenue drive outsized EPS leverage. If the full program delivers about C$65–70M a year (implied by Phase 1 being about 30% of a roughly C$20M-per-tranche opportunity) on a revenue base of about C$2.9–3.0B, adjusted EFO margin could rise by roughly 230 bps from cost alone. That would take it toward about 13% before any volume recovery. At about 15x adjusted earnings the market is not paying for this.

  2. Structural growth vectors are real and accelerating. Energy revenue doubled in FY2026 and energy backlog rose 40%. Radiopharma bookings recur. Non-GLP-1 life-sciences book-to-bill is about 1.1x. Services are growing double digits (+11.4% in Q1 FY2027). About 80% of backlog is in regulated markets with high switching costs.

  3. Cash generation and valuation give downside support. FY2026 free cash flow of C$371.7M equals about 15% of today's market cap. Leverage is within range, the NCIB is active (8.2M-share authorization) and EV/EBITDA is about 9x. Even normalized FCF of C$200–250M implies a high-single to low-double-digit FCF yield.

Bear case

  1. The growth reset may be cyclical and structural, not timing. GLP-1 capacity has been built, EV is gone, tomato processing is rolling over, and backlog is down 8.7% year over year to C$1,889M. Q1 missed the bottom of guidance and Q2 is guided lower still. "Modest growth" for FY2027 looks increasingly unlikely.

  2. Execution and governance credibility is impaired. The company has had material weaknesses for two consecutive years, an interim CFO since February 2026, four consecutive years of "non-recurring" restructuring (C$23–28M a year), restructuring slippage in Q1 FY2027, project disputes (EV settlement, Andersen) and a securities investigation. Adjusted metrics may persistently overstate economic earnings.

  3. Leverage may tighten as EBITDA falls. Net debt/EBITDA has risen from 2.8x to 2.9x and the trailing EBITDA trend is down. Restructuring cash costs come ahead of savings, and interest consumes about one-third of adjusted EFO. A further revenue miss could push leverage above 3x, constraining M&A and buybacks just as management wants to deploy capital.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Q2 FY2027 resultsEarly November 2026 (expected)Revenue versus C$660M–C$700M; bookings rebound (large-award conversion); adjusted EFO margin; operating cash flow
Fixed Cost Transformation Program, Phase 2+ disclosureFY2027Total savings quantification, program cost, site closures beyond Europe
Permanent CFO appointmentPendingCalibre and timing; stabilization of the finance function
Material weakness remediationBy FY2027 year-end (31 March 2027)Successful ERP upgrade; clean ICFR opinion in the FY2027 40-F
Sale of held-for-sale facilitiesFY2027Proceeds versus the C$61.4M carrying value; funding of restructuring
Nuclear and SMR awardsRollingRefurbishment and SMR fuel-fabrication orders; energy bookings recovery after Q1 FY2027's decline
GLP-1 versus non-GLP-1 life-sciences mixQuarterlyStabilization of life-sciences revenue; radiopharma and pharma bookings
USMCA review / U.S. tariffsOngoingAny change in Section 232/301 tariffs that affects the roughly 20% of revenue crossing the border
Securities investigationOngoingWhether a class action is filed
NCIB execution and M&AOngoingPace of buybacks versus leverage; resumption of bolt-on M&A
FY2027 full-year results and FY2028 outlookMay 2027Delivery of the margin uplift; updated long-term targets

Analyst verdict

ATS Corporation is a fundamentally sound franchise going through a poorly timed transition. On the positive side, it has assembled real competitive assets: a C$1.5B life-sciences automation business with validated-process know-how, a services and spares stream above C$1B, proprietary platforms (SuperTrak, Comecer, SP, CFT, IWK), and credible positions in the two most interesting long-cycle capex themes of the decade, nuclear power and radiopharmaceuticals. FY2026 showed what the business can do when working capital behaves: C$372M of free cash flow and leverage cut from 3.9x to 2.8x.

The problem is that three things are happening at once. Revenue is resetting as EV disappears, GLP-1 capacity normalizes and food processing cools. The cost base was sized for a C$3B+ business with EV programs. Leadership and control credibility has been dented by CEO and CFO turnover, two years of material weaknesses, and a Q1 FY2027 guidance miss followed by slipping restructuring. The roughly 64% fall from the 52-week high reflects all three.

At about 9x EV/EBITDA, about 15x adjusted earnings and about 1.3x book, the valuation already discounts a prolonged margin plateau near 10%. Doug Wright's Fixed Cost Transformation Program is the correct prescription. His Honeywell and Indicor background suggests disciplined portfolio and footprint management, and Phase 1 alone (about C$20M a year) is meaningful against FY2026 adjusted net income of C$165.5M.

However, the investment case now depends on execution evidence that does not yet exist: bookings recovering above C$700M a quarter, a permanent CFO, clean controls and quantified Phase 2 savings. Our stance is Neutral with a positive bias. ATS is an attractive self-help and recovery candidate for patient capital, but sizing should wait for one or two quarters of proof that revenue has bottomed and that cost savings are reaching the P&L rather than being absorbed by recurring "one-time" charges.


End of dossier. All figures are in C$ and on an IFRS basis unless noted. Adjusted measures are ATS non-IFRS measures as defined in its filings. Third-party and market data are point-in-time estimates and should be refreshed before investment use.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundAge

Doug Wright

Chief Executive Officer and Director

Since 14 January 2026

CEO of Indicor (diversified industrial solutions, from April 2023); President & CEO, Building Technologies at Honeywell International; President & CEO of Source Photonics; leadership roles at United Technologies (now RTX) and Ingersoll Rand

54 (Simply Wall St)

Anne Cybulski

Interim Chief Financial Officer; VP and Corporate Controller

Interim CFO since 15 February 2026 (also interim CFO from August 2025 to January 2026); joined ATS 2009; Corporate Controller since 2022

Progressive ATS finance roles

—

Sarah Moore

Group Executive, Life Sciences

—

Represented ATS at the Jefferies Industrials Conference, September 2026

—

Jeff Adamson

Senior officer (insider filer)

—

Bought 953 shares at C$39.12 on 7 July 2026

—

Giuseppe (Joe) Tassone

Senior officer (insider filer)

—

Sold 4,842 shares at C$41.55 on 2 June 2026

—

David Ocampo

Head of Investor Relations

—

Succeeded David Galison

—

Matthew Robinson

Director, Corporate Affairs & Communications

———

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

7 July 2025

CEO Andrew Hider to step down by end-August 2025

Left to lead Baxter International after about 8 years as ATS CEO (from 2017). CFO Ryan McLeod named interim CEO; Anne Cybulski interim CFO.

FY2026 Q2

C$7.3M stock-based compensation forfeiture

Reversal of previously recorded expense on the former CEO's departure.

16 December 2025

Doug Wright appointed CEO, effective on or before 14 January 2026

Comprehensive board-led search. Chair Michael Martino cited Wright's operating discipline and fit with the ABM. CEO inducement costs: C$1.3M in Q4 FY2026 and C$1.4M in Q1 FY2027.

19 January 2026

CFO Ryan McLeod resigns, effective 15 February 2026

Joined CAE Inc. as CFO effective 23 February 2026. McLeod had about 18–20 years at ATS, including CFO from 2020, and led the U.S. IPO and 18 acquisitions. Cybulski named interim CFO; permanent search under way. As of October 2026 no permanent appointment was found in this research.

Board of Directors

NameRoleNotes

Michael Martino

Chair of the Board

Quoted as Chair in the December 2025 and January 2026 releases

Doug Wright

Director (CEO)

Appointed December 2025 / January 2026

Major Shareholders

HolderSharesValue / noteSource

Royal Bank of Canada (RBC Global Asset Management)

7,761,838

About US$218.9M; roughly 7.9% of outstanding

MarketBeat (13F-based), October 2026

Undisclosed holder (named in the MarketBeat summary but not in excerpt)

7,168,112

About US$202.1M; roughly 7.3%

MarketBeat, October 2026

Janus Henderson Group

2,297,214

Added 1,435,375 shares

MarketBeat, October 2026

TD Asset Management

1,193,208

About US$32.9M

MarketBeat, September 2026

Other top-10 holders

—

Not publicly disclosed in the documents reviewed; full register via SEDI/13F/early-warning filings

—

Competitive Landscape

Competitors by Segment

VerticalNamed competitorsPositioning vs ATS

Life Sciences: device assembly and pharma equipment

Syntegon (private), Körber Pharma (private), IMA Group (private), Optima Packaging (private), Groninger (private), Bausch+Ströbel (private), Teamtechnik (Dürr Group), Jabil Healthcare (contract manufacturer)

ATS is among the leading independent auto-injector and wearable assembly specialists. European family-owned peers are strong in fill-finish where ATS is weaker.

Radiopharmaceuticals

Tema Sinergie (private), Getinge (isolators), Comecer is ATS's own brand

ATS holds a top-tier position via Comecer.

Lab equipment

Thermo Fisher Scientific, Azbil Telstar (lyophilizers), GEA (pharma freeze-dryers), IMA Life

SP Scientific is a niche leader; it competes with much larger scientific-equipment groups.

Consumer / packaging / warehouse

Coesia (private), Syntegon, Krones (packaging), Pro Mach (private), Duravant (private), regional integrators

ATS is a mid-scale player that differentiates through SuperTrak and high-speed assembly.

Food & Beverage processing

GEA Group, JBT Marel, Krones, Tetra Pak (Tetra Laval), Bertuzzi (private)

CFT is strong in tomato processing; it faces larger peers in broader food processing.

Energy / nuclear

Specialized nuclear engineering firms; Canadian nuclear supply chain (e.g., AtkinsRéalis, BWXT-related suppliers, Kinectrics)

ATS is a niche automation and tooling specialist rather than a prime contractor.

Transportation / EV (de-emphasized)

Comau, Dürr (assembly), ThyssenKrupp Automation Engineering, KUKA Systems, Manz, regional integrators

ATS is exiting dilutive work in this market.

Industrial automation and digital

Rockwell Automation (including its systems-integration and MES businesses), Siemens, Emerson, Accenture Industry X, regional integrators

PA, IPCOS and Illuminate compete in MES and process-control integration.

Peer Comparison FY2026

MetricATS (FY2026, C$)Rockwell Automation (FY2024, US$)Dürr AG (FY2024, €)GEA Group (FY2024, €)

Revenue (billions, local currency)

2.97

about 8.3

about 4.7

about 5.4

Organic / reported growth

+6.0% organic

about -9% reported

about +1% reported

about -0.5% reported

Margin reference

Adjusted EBITDA 13.9%

Segment operating margin about 20%

EBIT margin (pre-extraordinary) about 5–6%

EBITDA (pre-restructuring) about 15–16%

R&D intensity

Not disclosed (intangible additions about 1.5%)

about 7%

about 3–4%

about 3%

Listing

TSX/NYSE

NYSE

XETRA

XETRA

Company Snapshot

7,000

Employees

$1,730M

Market Cap

1978

Founded

Cambridge, Canada

Headquarters

SWOT Analysis

Strengths

  • Scale in life sciences. Life-sciences adjusted revenue was C$1,522.0M in FY2026 (51.2% of total), with C$1,103M of backlog at Q1 FY2027. Non-GLP-1 life-sciences bookings grew at a high-single-digit rate in Q1 FY2027 (Q1 FY2027 release).
  • High reoccurring and service mix. Services including spares were C$1,009.3M in FY2026, about 34% of revenue, up from 26.6% in FY2023 (C$686.9M). Services revenue grew 11.4% in Q1 FY2027 despite the overall decline.
  • Strong cash generation when working capital normalizes. FY2026 free cash flow was C$371.7M on operating cash flow of C$448.4M. The non-cash working capital ratio fell from 22.4% to 12.1% (FY2026 release).
  • Momentum in nuclear and energy. Energy revenue rose 82.7% in FY2026 to C$226.6M, and energy backlog rose to C$260M from C$186M. Q1 FY2027 energy revenue grew 68.9%.
  • Proprietary product platforms. Products and equipment revenue was C$927.1M in FY2026, up 14.1% year over year.
  • Diversified geography. Asia/Other revenue grew 26.3% in FY2026 to C$391.0M. No region exceeds 53% of revenue.
  • Leverage within target despite turbulence. Net debt/EBITDA improved from 3.9x at FY2025 to 2.8x at FY2026 and 2.9x at Q1 FY2027, within the 2–3x range.

Weaknesses

  • Margin compression. The adjusted EFO margin fell from 13.3% (FY2023) to 10.6% (FY2026) and 9.8% (Q1 FY2027).
  • Persistent "non-recurring" charges. Restructuring has been C$22.8M–C$27.5M a year for four years. FY2026 adjusting items to EFO totalled C$115.6M (calculated: C$314.4M adjusted EFO less C$198.8M IFRS EFO).
  • SG&A creep. SG&A rose from 17.3% of revenue in FY2023 to 20.9% in FY2026 (C$445.2M to C$620.3M).
  • Internal control failures. Material weaknesses existed at FY2025 (ICFR and disclosure controls ineffective). One remained at FY2026 (ERP transition in an international division), with an adverse auditor ICFR opinion (FY2026 40-F).
  • Leadership instability. CEO and CFO departures within 7 months (July 2025 and January 2026). The CFO has been interim since February 2026.
  • Guidance credibility. Q1 FY2027 revenue of C$693.7M came in below the C$700M–C$740M guided range. Restructuring timing slipped into Q2–Q3 FY2027.
  • Goodwill-heavy balance sheet. Goodwill and intangibles of C$2.10B are 118% of equity (C$1.78B) at FY2026. Tangible book value is negative.

Opportunities

  • Fixed Cost Transformation Program. Phase 1 targets about C$20M a year, with an implied total of about C$65–70M a year. The program is meant to deliver about half the gap to a 15% adjusted EFO margin (Q1 FY2027 release).
  • Nuclear and SMR build cycle. ATS is engaged in FEED and prototype work for SMRs and new builds and sees fuel fabrication as a complementary opportunity. Energy backlog rose 40% year over year at FY2026.
  • Radiopharmaceutical commercialization. Management sees strong interest in production, containment and automation as programs move from clinical to commercial scale (Q1 FY2027 outlook).
  • Redeploying transportation capabilities (laser welding, vision, precision test) into data-center infrastructure and warehouse automation. Consumer products revenue grew 64.7% in FY2026.
  • Services capture from embedding service in operating units. The aim is to move reoccurring revenue toward or above the top of the 25–35% band.
  • Undemanding valuation enables accretive buybacks. 1.12M shares repurchased at C$27.97 through August 2026; the stock now trades at about 1.3x book and about 9x EV/EBITDA (calculated, Section 21).
  • Bolt-on M&A in fragmented niches once leverage permits. Management says M&A and restructuring will run concurrently.

Threats

  • GLP-1 capacity normalization. Lower GLP-1-related demand weighed on Q1 FY2027 life-sciences revenue (-8.7%).
  • Trade policy. Just over 20% of adjusted revenue is Canadian and European product sold into the U.S. The U.S. declined to extend USMCA in 2026, triggering annual reviews; Section 232, 301 and other tariffs are in play (Q1 FY2027).
  • Order-award timing. Bookings fell 18.4% in Q4 FY2026 and 5.3% in Q1 FY2027. Backlog fell 8.7% year over year to C$1,889M.
  • Securities litigation. The Levi & Korsinsky investigation followed the 26.6% share drop on 6 August 2026.
  • Project disputes. The Andersen Corp. lawsuit over delivery delays and the FY2025 EV customer settlement of C$171.1M.
  • Competition from well-capitalized private European machine builders (Syntegon, Körber, IMA, Coesia) and large diversified groups.
  • Cyclical F&B investment. Tomato-processing investment is slowing after elevated recent levels; F&B revenue fell 15.5% in Q1 FY2027.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q1 FY2026 (Apr–Jun 2025)Revenue C$736.7M; net income C$24.3M; adjusted EPS C$0.41; bookings C$693M; C$175M of debt repaid; C$10M of shares repurchasedStrong start; deleveraging begins
7 July 2025CEO Andrew Hider to depart by end-August to lead Baxter; Ryan McLeod named interim CEOLeadership uncertainty
August 2025Participation in Raymond James, Jefferies, RBC and Morgan Stanley Laguna conferencesInvestor outreach under interim leadership
5 November 2025Q2 FY2026 results: strong organic revenue growth; net income about C$33.7M (calculated)Recovery continues; Q3 revenue guided at C$700M–C$740M
November–December 2025Scotiabank, Baird, UBS and Goldman Sachs industrials conferences—
16 December 2025Doug Wright appointed CEOOutside operator with Honeywell and Indicor portfolio-management background
18 December 2025NCIB approved by the TSX (up to 8,225,621 shares, as announced)Capital-return signal
14 January 2026Wright assumes the CEO role—
19 January 2026CFO Ryan McLeod resigns to join CAE; Anne Cybulski named interim CFO from 15 FebruarySecond senior departure in 6 months
4 February 2026Q3 FY2026: revenue and EPS beat; net income C$29.9M (C$0.30) vs C$6.4M a year earlier; Wright outlines margin prioritiesPositive inflection; leverage back in range
March 2026Raymond James and TD Cowen conferences—
Q4 FY2026Transportation reorganization: assets held for sale, facility consolidation, C$28.3M chargePortfolio clean-up
27 May 2026FY2026 audit: unqualified financial statements; adverse ICFR opinion (one material weakness tied to an ERP transition in an international division)Controls risk persists for a second year
28 May 2026FY2026 results: revenue C$2,972.9M; net income C$71.7M; adjusted EPS C$1.69; FCF C$371.7M; leverage 2.8x. Q4 adjusted EPS C$0.36 vs C$0.44 consensus; Q1 FY2027 guidance C$700M–C$740M below consensus (about C$759M)Shares fell about 11.5% intraday
29 May 2026RBC trims its target from US$51 to US$50 (Outperform)Still constructive
June 2026Zacks downgrades to Strong Sell (9 June); Desjardins initiates coverage (16 June)Mixed sentiment
7 July 2026Insider purchases by Jeff Adamson and Anne CybulskiInsider confidence
6 August 2026Q1 FY2027: revenue C$693.7M (below the guidance floor); net loss C$0.3M; adjusted EPS C$0.35; bookings C$656M; backlog C$1,889M. Fixed Cost Transformation Program announced; Industrial & Consumer vertical created; Q2 guidance C$660M–C$700MShares fell about 26.6%, the largest one-day drop in years
6 August 2026AGM: board, auditor and say-on-pay approvedGovernance continuity
7 August 2026Stifel cuts its target from C$52 to C$44 (Buy)—
10 August 2026TD Securities downgrades Buy to Hold; RBC cuts its target from C$50 to C$41Sell-side capitulation
10 August 2026Levi & Korsinsky opens a securities investigation over disclosure of operating and internal-control risksLitigation overhang (investigation only; no filed class action identified)
17–24 August 2026TSX shares set new 52-week lows (C$27.31, then C$26.48)—
3 September 2026NCIB update: 1,119,413 shares bought at an average of C$27.97 through AugustBuyback activity into weakness
10 September 2026Interim CFO and Life Sciences Group Executive present at the Jefferies Industrials Conference—
29 September 2026NYSE 52-week low of US$18.34—
7 October 2026NYSE 52-week low of US$17.72; market cap about US$1.73BShares down about 64% from the 52-week high on the TSX (C$49.48)

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue IFRS rose from CAD 2,182.7 Mn in FY2022 to CAD 2,972.9 Mn in FY2026.
ATS Corporation — Income Statement: Revenue & Gross Profit
Series (CAD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue IFRS2,182.72,577.43,032.92,533.32,972.9
Adjusted revenue2,182.72,577.43,032.92,680.22,970.1
Cost of revenues—1,851.62,177.41,886.62,122.1
Gross profit—725.8855.5646.7850.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.